Vertex Pharmaceuticals Incorporated (LON:0QZU)
 416.83
 -3.15 (-0.75%)
  At close: Oct 29, 2025
Vertex Pharmaceuticals Employees
Vertex Pharmaceuticals had 6,100 employees as of December 31, 2024. The number of employees increased by 700 or 12.96% compared to the previous year.
Employees 
 6,100
Change (1Y) 
 700
Growth (1Y) 
 12.96%
Revenue / Employee 
 1.37M GBP
Profits / Employee 
 435.26K GBP
Market Cap 
81.89B
Employees Chart
Employees History
| Date | Employees | Change | Growth | 
|---|---|---|---|
| Dec 31, 2024 | 6,100 | 700 | 12.96% | 
| Dec 31, 2023 | 5,400 | 600 | 12.50% | 
| Dec 31, 2022 | 4,800 | 900 | 23.08% | 
| Dec 31, 2021 | 3,900 | 500 | 14.71% | 
| Dec 31, 2020 | 3,400 | 400 | 13.33% | 
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
Related Stocks
| Company Name | Employees | 
|---|---|
| AstraZeneca | 94,300 | 
| GSK plc | 68,629 | 
| Haleon | 24,561 | 
| Smith & Nephew | 17,349 | 
| Spire Healthcare Group | 15,703 | 
| ConvaTec Group | 10,489 | 
| Hikma Pharmaceuticals | 9,500 | 
| Genus | 3,190 | 
Vertex Pharmaceuticals News
- 6 days ago - JEPQ, ADI, VRTX, ORLY: Large Outflows Detected at ETF - Nasdaq
- 7 days ago - Vertex Presents New Data Across Portfolio of Cystic Fibrosis Medicines Including ALYFTREK® at the North American Cystic Fibrosis Conference - Business Wire
- 8 days ago - Insiders Bullish on Certain Holdings of JDOC - Nasdaq
- 8 days ago - Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It - Nasdaq
- 9 days ago - ClearBridge Select Strategy buys REGN, VRTX & VST; exits ICLR, PCTY & ADBE - Seeking Alpha
- 13 days ago - Vertex Pharmaceuticals (VRTX) Advances Povetacicept for Kidney Disease Treatment - GuruFocus
- 13 days ago - Vertex Pharmaceuticals (VRTX) Advances Development of Key Therapeutic - GuruFocus
- 13 days ago - Vertex IgA nephropathy asset povetacicept granted FDA rolling review - Seeking Alpha